Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
DMAC
DMAC
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
DMAC News
DiaMedica Therapeutics Grants 50,000 Stock Options to New Employee
Jan 16 2026
Businesswire
DiaMedica Therapeutics Grants 50,000 Stock Options to New Employee
Jan 16 2026
Yahoo Finance
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Dec 19 2025
NASDAQ.COM
DiaMedica Engages FDA for DM199 Preclinical Study Clarity
Dec 18 2025
Newsfilter
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Dec 09 2025
NASDAQ.COM
DiaMedica Therapeutics to Attend Jefferies Global Healthcare Conference in London
Nov 10 2025
Newsfilter
DiaMedica Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(C)(4)
Sep 29 2025
Newsfilter
DiaMedica Therapeutics, Inc. (DMAC) Shows Strong Momentum: Is It a Good Investment?
Sep 17 2025
NASDAQ.COM
Reasons to Consider DiaMedica Therapeutics, Inc. (DMAC) as a Strong Momentum Stock: Is It Time to Buy?
Aug 28 2025
NASDAQ.COM
HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Target
Aug 15 2025
Benzinga
DiaMedica Posts Narrower Loss in Q2
Aug 13 2025
NASDAQ.COM
DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
Aug 12 2025
Newsfilter
DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer
Aug 06 2025
Newsfilter
DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement
Jul 23 2025
Newsfilter
Craig-Hallum Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $11
Jul 18 2025
Benzinga
Lake Street Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $14
Jul 18 2025
Benzinga
Show More News
